News


Mol Cell, PLOS Genet, Mol Cell, FASEB J, EMBO Mol Med: our 5 latest publications

Category: Highlighted publications at the CRCM

RAD51 Is an Essential Mediator of Alternative Lengthening of Telomeres.

Barroso-González J, García-Expósito L, Hoang SM, Lynskey ML, Roncaioli JL,

Ghosh A, Wallace CT, Modesti M, Bernstein KA, Sarkar SN, Watkins SC, O'Sullivan

RJ.

Mol Cell. 2019 Oct 3;76(1):11-26.e7. doi: 10.1016/j.molcel.2019.06.043

www.ncbi.nlm.nih.gov/pubmed/31400850

 

Differential Requirements for the RAD51 Paralogs in Genome Repair and Maintenance in Human Cells.

Garcin EB, Gon S, Sullivan MR, Brunette GJ, Cian A, Concordet JP, Giovannangeli C, Dirks WG, Eberth S, Bernstein KA, Prakash R, Jasin M, Modesti M.

PLoS Genet. 2019 Oct 4;15(10):e1008355.

www.ncbi.nlm.nih.gov/pubmed/31584931

 

 

SLX4IP Antagonizes Promiscuous BLM Activity during ALT Maintenance.

Panier S, Maric M, Hewitt G, Mason-Osann E, Gali H, Dai A, Labadorf A, Guervilly JH, Ruis P, Segura-Bayona S, Belan O, Marzec P, Gaillard PL, Flynn RL, Boulton SJ.

Mol Cell. 2019 Oct 3;76(1):27-43.e11.

www.ncbi.nlm.nih.gov/pubmed/31447390

 

PML hyposumoylation is responsible for the resistance of pancreatic cancer.

Swayden M, Alzeeb G, Masoud R, Berthois Y, Audebert S, Camoin L, Hannouche L, Vachon H, Gayet O, Bigonnet M, Roques J, Silvy F, Carrier A, Dusetti N, Iovanna JL, Soubeyran P.

FASEB J. 2019 Sep 16:fj201901091R.

www.ncbi.nlm.nih.gov/pubmed/31557059

 

A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells.

Arfaoui A, Rioualen C, Azzoni V, Pinna G, Finetti P, Wicinski J, Josselin E, Macario M, Castellano R, Léonard-Stumpf C, Bal A, Gros A, Lossy S, Kharrat M, Collette Y, Bertucci F, Birnbaum D, Douik H, Bidaut G, Charafe-Jauffret E, Ginestier C.

EMBO Mol Med. 2019 Sep 2:e9930. doi: 10.15252/emmm.201809930.

www.ncbi.nlm.nih.gov/pubmed/31476112

 

 

 

A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells.

Arfaoui A, Rioualen C, Azzoni V, Pinna G, Finetti P, Wicinski J, Josselin E, Macario M, Castellano R, Léonard-Stumpf C, Bal A, Gros A, Lossy S, Kharrat M, Collette Y, Bertucci F, Birnbaum D, Douik H, Bidaut G, Charafe-Jauffret E, Ginestier C.

EMBO Mol Med. 2019 Sep 2:e9930. doi: 10.15252/emmm.201809930.

www.ncbi.nlm.nih.gov/pubmed/31476112



Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine.

Lomberk G, Dusetti N, Iovanna J, Urrutia R.

Nat Commun. 2019 Aug 28;10(1):3875. doi: 10.1038/s41467-019-11812-7. 

www.nature.com/articles/s41467-019-11812-7



Immune evasion before tumour invasion in early lung squamous carcinogenesis.

Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G, Buttard B, othe F , Willard-Gallo K, Haller A, Ninane V, Burny A, Sculier JP, Spira A, Galon J

Nature. 2019 Jun 26. doi: 10.1038/s41586-019-1330-0. 

www.ncbi.nlm.nih.gov/pubmed/31243362


Sensitive and easy screening for circulating tumor cells by flow cytometry.

Lopresti A, Malergue F, Bertucci F, Liberatoscioli ML, Garnier S, DaCosta Q, Finetti P, Gilabert M, Raoul JL, Birnbaum D, Acquaviva C, Mamessier E.

JCI Insight. 2019 Jun 13;5. pii: 128180. doi: 10.1172/jci.insight.128180.

www.ncbi.nlm.nih.gov/pubmed/31194699 



Genomic characterization of metastatic breast cancers.

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Tran Dien A, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Tabernero J, Chia S, Martinalbo J, Perez-Moreno P, Dogan S, Verret B, Chaffanet M, Bacelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron D, Le Tourneau C & André F.

Nature 2019, doi.org/10.1038/s41586-019-1056-z  



Ligand-based design of a potent inhibitor of NUPR1 exerting anticancer activity via necroptosis

Santofimia-Catano P, Xia Y, Lan W, Zhou Z, Huang C, Peng L, Soubeyran P, Velazquez-Campoy A, Abian O, Rizzuti B, Neira JL, Iovanna JL.

Journal of Clinical Investigations 2019, doi.org/10.1172/JCI127223

www.ncbi.nlm.nih.gov/pubmed/30920390